$45,106,864
OSELTAMIVIR PHOSPHATE (TAMIFLU) 30MG AND 75MG CAPSULES
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Modification to the 2025 Tamiflu-procurement contract providing antiviral medications for pandemic stockpiling.
U.S. pandemic response capacity depends on adequate antiviral stockpiles; Tamiflu is a key tool against influenza pandemics.
Single-source risk: Roche (Swiss-owned) dominates oseltamivir production; U.S. pandemic preparedness depends on foreign pharmaceutical supply.
China has developed domestic oseltamivir production; U.S. reliance on Roche reflects vulnerabilities in Western pharmaceutical supply chains.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-06-11. Cost: $0.011664.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50325F80003_7505_36F79723D0219_3600.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.